SR9009 has antitumoractivity in small cell lung cancer by targeting Reverb alpha through the suppression of autophagy gene Atg5 [5].Based on literature review, we have been taken Reverbα as a breast cancer target for docking analysis. This evidence concerns the gene NR1D1 and breast carcinoma.